Press "Enter" to skip to content

New patent for NOVO drug XULTOPHY 100/3.6

0
Copyright © DrugPatentWatch. Originally published at New patent for NOVO drug XULTOPHY 100/3.6

Annual Drug Patent Expirations for XULTOPHY+100%2F3.6
Annual Drug Patent Expirations for XULTOPHY+100%2F3.6

Xultophy 100/3.6 is a drug marketed by Novo and is included in one NDA. It is available from one supplier. There are eighteen patents protecting this drug.

Drug patent litigation for XULTOPHY 100/3.6.

This drug has two hundred and fifty-eight patent family members in twenty-seven countries.

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. One supplier is listed for this compound. Additional details are available on the insulin degludec; liraglutide profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Copyright © DrugPatentWatch. Originally published at New patent for NOVO drug XULTOPHY 100/3.6
    Do NOT follow this link or you will be banned from the site!